- Home
- FIZZ vs DNLI Comparison
FIZZ vs DNLI Comparison
Compare FIZZ & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FIZZ | DNLI |
|---|---|---|
| Founded | 1985 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.7B |
| IPO Year | 1994 | 2017 |
Fundamental Metrics
Financial Performance| Metric | FIZZ | DNLI |
|---|---|---|
| Price | $31.58 | $24.23 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | ★ $35.00 | $34.33 |
| AVG Volume (30 Days) | 336.7K | ★ 1.4M |
| Earning Date | 03-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.96 | N/A |
| Revenue | ★ $1,180,552,000.00 | N/A |
| Revenue This Year | $0.14 | N/A |
| Revenue Next Year | $3.33 | $408.85 |
| P/E Ratio | $15.83 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.01 | $12.58 |
| 52 Week High | $46.91 | $27.30 |
Technical Indicators
Market Signals| Indicator | FIZZ | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 46.67 | 49.15 |
| Support Level | $31.21 | $22.32 |
| Resistance Level | $35.74 | $25.74 |
| Average True Range (ATR) | 0.75 | 0.84 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 42.34 | 47.31 |
Price Performance
Historical ComparisonAbout FIZZ National Beverage Corp.
National Beverage Corp is a non-alcoholic beverage company in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls the majority of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for retailers, direct-store delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants).
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.